NovoCure/NVCR

$14.90

-2.49%
-
1D1W1MYTD1YMAX

About NovoCure

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Ticker

NVCR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Asaf Danziger

Employees

1,453

Headquarters

Saint helier, Jersey

NovoCure Metrics

BasicAdvanced
$1.63B
Market cap
-
P/E ratio
-$1.95
EPS
0.41
Beta
-
Dividend rate

What the Analysts think about NovoCure

Analyst Ratings

Majority rating from 7 analysts.
Hold

Price Targets

Average projection from 7 analysts.
75.44% upside
High $49.00
Low $14.00
$14.90
Current price
$26.14
Average price target

NovoCure Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-35.15% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$133.7M
5.03%
Net income
$-47M
-4.86%
Profit margin
-35.15%
-9.41%

NovoCure Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 12.38%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q1 24
Actual
-$0.50
-$0.54
-$0.46
-
Expected
-$0.32
-$0.50
-$0.53
-$0.43
Surprise
54.5%
7.91%
-12.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell NovoCure stock

Buy or sell NovoCure stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing